Compare MATW & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | IRWD |
|---|---|---|
| Founded | 1850 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.4M | 663.6M |
| IPO Year | 1995 | 2009 |
| Metric | MATW | IRWD |
|---|---|---|
| Price | $25.35 | $3.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 222.9K | ★ 2.5M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | 59.07 | ★ 1400.00 |
| EPS | ★ 0.69 | 0.24 |
| Revenue | ★ $1,795,737,000.00 | $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | $36.87 | ★ $13.50 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $20.76 | $0.58 |
| 52 Week High | $30.93 | $5.78 |
| Indicator | MATW | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 40.18 |
| Support Level | $25.38 | $3.02 |
| Resistance Level | $26.34 | $3.53 |
| Average True Range (ATR) | 0.78 | 0.19 |
| MACD | -0.21 | -0.06 |
| Stochastic Oscillator | 14.80 | 26.04 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.